In preclinical models, IL-33 delays metastatic progression of peritoneal cancer via induction of an allergic tumor microenvironment in which eosinophils, CD4+ T cells, and macrophages contribute to anti-tumoral effects (62). The gene discussed is CD4; the disease is peritoneum cancer.